Navigation Links
Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
Date:9/19/2007

DANBURY, Conn., Sept. 19 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that it will amend its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2007 to correct the manner in which the Company recorded non-cash share-based compensation expense arising from stock options granted to non-employee directors at the time of the Company's initial public offering. The amendment will increase share-based compensation expense and is solely non-cash in nature.

On May 10, 2007, the Company granted options to purchase an aggregate of 200,000 shares of common stock at an exercise price of $15.00 (which was the price per share to the public in the Company's initial public offering). Pursuant to the terms of the Company's 2005 Non-Employee Directors' Stock Option Plan, all of the options were fully vested on the date of grant. Accordingly, the Company should have recorded non-cash share-based compensation expense of approximately $1.7 million. The Company recorded non- cash share-based compensation expense related to these options as if the options were to vest over a two-year period, as had been the case with earlier option grants to the Company's non-employee directors. Accordingly, in the third quarter of 2007, the Company only recorded approximately $0.1 million of share-based compensation expense related to these options and the Company would have recorded the remaining $1.6 million of previously disclosed unamortized expense ratably over such two-year period.

As a result, the Company will file amended unaudited financial statements to record additional non-cash share-based compensation expense of approximately $1.6 million for the three- and nine-month periods ended June 30, 2007. The effect of this amendment will be to increase the Company's general and administrative expenses and net loss applicable to common stockholders for these periods by $1.6 million from the previously reported amounts. In addition, the Comp
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Amendment on cloning ban rejected; vote on bill set for Wednesday
2. New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes
3. Multichannel Pipetting: How to Choose the Correct Pipettor
4. Mental research at UW-Madison could correct disabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...ISBANE, Calif., July 24 /- ...hat it will release second quarter 2008,financial ... July 31, 2008,at 4:00 p.m. Eastern time. A live c...Mune at 4:30 p.m. Eastern time that same day., To... (U.S.) or,706-634-0154 (international), conferenc...
(Date:7/24/2008)... Healthcare Technology Veteran to Help Spearhe...alth Monitoring Systems (HMS), (http://www.hmsinc....said today,that Karen S. Dockrell has been appoint...han 17 years of experience in sales, sales,managem...care technology,medical device and pharmaceutical...
(Date:7/24/2008)...DFORD, Mass., July 24 /- Ho...uccessful completion of the tender,offer by its di...for all,outstanding shares of Third Wave Technolog...r share in cash., The subsequent offering period ...Wednesday, July 23, 2008. The initial tender offer...
(Date:7/24/2008)...sue Dissection System Represents Important Advance... Technologies -, PALO ALTO, Calif., July 24 /PRNe...ompany that has developed a new tissue dissection ...nounced that the U.S. Food and,Drug Administration...t its,PEAK(R) Surgery System for use in general su...
Breaking Biology Technology:InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31 2Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales 2Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc. 2Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc. 3Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc. 4PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 4
...portal to educational information about books and ...ward from the Association of Educational Publishe...evement in supplemental educational resources for ...in the Best Educational Website category titled "P...s.net is a provider of multimedia resources that s...
...t Corp. has closed on loans to help two Madison t...Universal Separators, Inc. , stretch scarce ventur...ture Debt Fund established earlier this year by MD...hard-to-finance small businesses. , ,A $200,000 l...t its data extraction and redaction software. The ...
...I have a number of juicy topics I wanted to review...e annual Israel biotech/medical device conference ...out Indian and my growing insights into the Indian...search that has crossed my transom (including musi...inally wanted to start writing this column. I real...
...lark CEO Darwin Smith may or may not have brought...e. , ,It was 1983, and Wisconsin had just elected ...pted to address a budget deficit with an income ta...the impact of high taxes on the state,s business c...lark,s corporate headquarters to Dallas, although ...
Other Biology Technology:MDC provides venture funding for tech companies 2The world of in vitro diagnostics is another Midwest success story 2The world of in vitro diagnostics is another Midwest success story 3The world of in vitro diagnostics is another Midwest success story 4The world of in vitro diagnostics is another Midwest success story 5The world of in vitro diagnostics is another Midwest success story 6RedPrairie: Will they stay, or will they go? 2RedPrairie: Will they stay, or will they go? 3RedPrairie: Will they stay, or will they go? 4
(Date:7/25/2008)...rsity of Houston department of health and human pe...econd Life (SL) thanks to grants from the UH Facul...etwork Culture Project of the University of Southe..., "These funds will allow our faculty to stake g...ts and our community," said Charles Layne, profess...
(Date:7/25/2008)...the need to translate basic science discoveries i...ew study by researchers at the Medical College of ...f Health (NIH) identified reasons why clinical sc...r reviews than basic science grant applications to...issue of The American Journal of Medicine . , I...
(Date:7/25/2008)...July 25, 2008) New research published in the July...Surgeons shows elevated plasma DNA is a reliable ...lso suggests that plasma DNA levels rise before cl...ty of patients. , Esophageal cancer, one of th...ally diagnosed at a late stage. An accurate marker...
(Date:7/24/2008)...nstitutional team led by Massachusetts General Hos... new tool for genomic research and medicine a rob...an target particular DNA sequences for inactivatio...Cell, the researchers describe an efficient, publ...finger nucleases (ZFNs), which can be used to indu...
Breaking Biology News(10 mins):Second Life a first for UH department of health and human performance 2New study spotlights National Institutes of Health grant outcomes for clinical research 2Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds 2Consortium develops new method enabling routine targeted gene modification 2Some Iraq War Vets Suffer Breathing Problems 19978 1Some Iraq War Vets Suffer Breathing Problems 19978 2Some Iraq War Vets Suffer Breathing Problems 19978 3The Quantum Group Completes Corporate Expansion Plan 3B Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 19974 1The Quantum Group Completes Corporate Expansion Plan 3B Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 19974 2The Quantum Group Completes Corporate Expansion Plan 3B Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 19974 3ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 19970 1ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 19970 2Dendreon Presents Preclinical Data Demonstrating Activity of Trp p8 agonist D 3263 in Benign Prostatic Hyperplasia 2155 1Dendreon Presents Preclinical Data Demonstrating Activity of Trp p8 agonist D 3263 in Benign Prostatic Hyperplasia 2155 2Dendreon Presents Preclinical Data Demonstrating Activity of Trp p8 agonist D 3263 in Benign Prostatic Hyperplasia 2155 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp p8 agonist D 3263 in Benign Prostatic Hyperplasia 2155 4
...dely touted as an eco-friendly, clean-burning fuel... fuel made primarily from ethanol instead of pure ... and hospitalizations would likely increase, accor...eric scientist Mark Z. Jacobson. His findings are ...urnal Environmental Science & Technology (ES&a...
...ancer Institute researchers have developed a power...regulating molecules called nucleosomes throughout...over important clues for understanding and diagnos... Moreover, it may shed light on the role of nucleo...ell to its original embryonic state, which is a cr...
...stematic Review of the use of electronic mosquito ... they work. The researchers therefore say that the...at there is no reason for even trying to do more r... when a person is bitten by an infected female mos...ents (EMRs) claim that the high pitch sound they e...
...gned to emulate the healing power of the sun could...te cancer as early as 2009. But it remains to be s...state cancer care that its makers claim. , The dr... given to patients in the advanced stages of prost...kers came up with the idea because vitamin D from ...
Other Biology News:Ethanol vehicles pose a significant risk to human health, study finds 2Ethanol vehicles pose a significant risk to human health, study finds 3Scientists map key landmarks in human genome 2Scientists map key landmarks in human genome 3Sunshine pill for prostate cancer in 2009 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity.
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles
IHC detection kit for PCNA in cells and tissues
Biology Products: